|
|
||||||||
Division of Pulmonary Diseases, University of Miami School of Medicine, Mount Sinai Medical Center, Miami Beach, Florida 33140
We have hypothesized that antiallergic activity of inhaled
heparin is molecular weight dependent and mediated by
"nonanticoagulant fractions" (NAF-heparin). Therefore, we studied
comparative effects of high-, medium-, and ultralow-molecular-weight
(HMW, MMW, and ULMW, respectively) NAF-heparins on acute
bronchoconstrictor response (ABR) and airway hyperresponsiveness (AHR)
in allergic sheep. Specific lung resistance was measured in 23 allergic
sheep, before and immediately after challenge with
Ascaris suum antigen, without and
after pretreatment with inhaled NAF-heparins. Airway
responsiveness was estimated before and 2 h postantigen as the
cumulative provocating dose of carbachol in breath units, which
increased specific lung resistance by 400%. NAF-heparins attenuated
ABR and AHR in a molecular-weight-dependent fashion. HMW NAF-heparin
(n = 8) was the least effective agent: it attenuated ABR [inhibitory dose causing 50% protection
(ID50) = 4 mg/kg] but had
no effect on AHR. MMW NAF-heparin (n = 8) showed intermediate efficacy (ABR
ID50 = 0.8 mg/kg, AHR
ID50 = 1.4 mg/kg), whereas ULMW
NAF-heparin (n = 7) was the most
effective agent (ABR ID50 = 0.4 mg/kg, AHR ID50 = 0.2 mg/kg). ULMW
NAF-heparin was 3.5 times more potent in attenuating antigen-induced
AHR when administered "after" antigen challenge and failed to
inhibit the bronchoconstrictor response to carbachol and histamine. In
15 additional sheep, segmental antigen challenge caused a marked increase in histamine in bronchoalveolar lavage fluid that was not
prevented by any of the inhaled NAF-heparins. These data indicate that
antiallergic activity of inhaled heparin is independent of its
anticoagulant action and resides in the <2,500 ULMW chains. The
antiallergic activity of NAF-heparins is mediated by an unknown biological action and may have therapeutic potential.
asthma; airway hyperresponsiveness; antigen-induced bronchoconstriction
This article has been cited by other articles:
![]() |
R. SUZUKI and A. N. FREED Heparin Inhibits Eicosanoid Metabolism and Hyperventilation-induced Bronchoconstriction in Dogs Am. J. Respir. Crit. Care Med., June 1, 2000; 161(6): 1850 - 1854. [Abstract] [Full Text] |
||||
![]() |
T. Ahmed, J. Ungo, M. Zhou, and C. Campo Inhibition of allergic late airway responses by inhaled heparin-derived oligosaccharides J Appl Physiol, May 1, 2000; 88(5): 1721 - 1729. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. AHMED, B. J. GONZALEZ, and I. DANTA Prevention of Exercise-induced Bronchoconstriction by Inhaled Low-molecular-weight Heparin Am. J. Respir. Crit. Care Med., August 1, 1999; 160(2): 576 - 581. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |